This is the authors' abstract. We don't add key points for this paper.
We have recently shown that in order to attain therapeutic efficacy by HSC gene therapy for Metachromatic Leukodystrophy (MLD), Arylsulfatase A (ARSA) over_expression in HSC and their progeny is required. The recent identification of Sulfatase Modifying Factor 1 (SUMF1) as a common activator of sulfatases and a rate_limiting factor in the biological activation of these enzymes, raises concerns for possible adverse effects of enzyme over_expression within certain cell type (Cosma M.P. et al., Cell 2003).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Capotondo et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: